Bladder Cancer Market, By Type (Transitional Cell Carcinoma, Invasive Bladder Cancer, Superficial Bladder Cancer, Adenocarcinomax, and Other Rare Types), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Radical Cystectomy, and Others), By Diagnosis (Urine Lab Tests, Cystoscopy, Biopsy, Imaging Test, and Others), By End User (Hospital, Clinic, Cancer Care Centers, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global Bladder Cancer market size was estimated at USD 5.25 billion in 2023 and is projected to reach USD 7.52 billion in 2030 at a CAGR of 4.60% during the forecast period 2023-2030.
Bladder cancer occurs when the cells that make up the bladder begin to multiply uncontrollably. More cancer cells can form a tumor and spread to other parts of the body over time. The bladder wall consists of several layers. Each layer consists of several types of cells. The urothelium, or transitional epithelium, lining the inside of the bladder is where most bladder malignancies begin. Cancer progresses to a higher stage, progresses, and is more difficult to treat when it spreads to or through other layers of the bladder wall. Over time, cancer can spread outside the bladder and into adjacent structures. It can spread to nearby lymph nodes or other organs.
The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life. Such initiatives are expected to boost market growth over the forecast period.
The spread of the COVID-19 pandemic had a significant impact on the bladder cancer market. During the first wave, the surgical volume was not compromised. Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. During the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics had been significantly impacted.
The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. Factors such as increasing incidence of bladder cancer, growing awareness about cancer and its available treatments, rising healthcare costs, increasing smoking and tobacco consumption are expected to accelerate the maturation of the global bladder cancer market. Additionally, the prevalence of bladder cancer across the world supports the expansion of the market during the forest season. For example, the Global Cancer Observatory Statistics 2020 reports that bladder cancer and prostate cancer are among the 10 most common cancers in the world. The same source also reports that the number of new cases of bladder cancer was estimated to be 573,278 in 2020 and the number of prostate cancer cases was 1,414,259 in both sexes in 2020. Such a high incidence of cancer worldwide will drive the market over time. Additionally, increasing focus of key players on various growth strategies such as R&D and product approval is expected to further boost the market. These factors have led to the expansion of the market and increased demand for Bladder Cancer solutions.
North America to Dominate the Market
Report Feature |
Descriptions |
---|---|
Growth Rate |
CAGR of 4.60% during the forecasting period, 2023-2030 |
Historical Data |
2019-2021 |
Forecast Years |
2023-2030 |
Base Year |
2022 |
Units Considered |
Revenue in USD billion and CAGR from 2023 to 2030 |
Report Segmentation |
type, Treatment, diagnosis, end user and region |
Report Attribute |
Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling |
Regional Level Scope |
North America, Europe, Asia-Pacific, South America, and Middle East, and Africa |
Country Level Scope |
U.S., Japan, Germany, U.K., China, India, Brazil, UAE, and South Africa (50+ Countries Across the Globe) |
Companies Profiled |
Abbott Inc., Accord Healthcare, Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd, Astellas Pharma Inc., AstraZeneca Plc, Bedford Lab, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Hoffmann-La Roche AG, Johnson & Johnson (Janssen Pharmaceutical), Merck & Co. Inc, Novartis International AG, Pfizer Inc., Sanofi S.A. |
Available Customization |
In addition to the market data for the Bladder Cancer Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements. |
The Bladder Cancer Market is segmented into various segments such as type, Treatment, diagnosis, end user, and region:
Based on Type
Based on the Treatment
Based on the Diagnosis
Based on End User
Based on Region
The prominent players in the Bladder Cancer market are